---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-25-000102"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:26.186960+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports Q2 net loss $14.4M; highlights 94% OS at 6 months in pancreatic cancer trial

## Summary
- Net loss of $14.4M ($0.40/share) vs $14.1M ($0.47/share) in Q2 2024; cash $26.4M as of June 30.
- 94% overall survival at 6 months in Phase 2a of atebimetinib + mGnP in first-line pancreatic cancer (n=34); median OS not reached.
- Third-line pancreatic cancer patient on atebimetinib monotherapy >18 months with confirmed partial response and 34% tumor reduction.
- US composition of matter patent granted for atebimetinib provides exclusivity into 2042; pivotal trial expected in 2026.
- Cash runway sufficient into 2026; End of Phase 2 meeting request submitted to FDA.

## SEC filing metadata
- accession: 0001790340-25-000102
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/0001790340-25-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/imrx-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-25-000102
- JSON: https://secwatch.observer/filing/0001790340-25-000102.json
- Plain text: https://secwatch.observer/filing/0001790340-25-000102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.